Research programme: cancer therapeutics - Simcere
Alternative Names: SIM-010603; SIM-0702; SIM-1005Latest Information Update: 05 Oct 2015
At a glance
- Originator Simcere Pharmaceutical Group
- Developer Simcere Pharmaceutical Group; Sun Yat-Sen University Cancer Center
- Class
- Mechanism of Action Angiogenesis inhibitors; Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 14 Aug 2015 Discontinued - Preclinical for Cancer in China (unspecified route)
- 01 Sep 2009 This programme is in active development
- 28 Mar 2006 Preclinical trials in Cancer in China (unspecified route)